Hepion Pharmaceuticals Statistics
Share Statistics
Hepion Pharmaceuticals has 6.96M shares outstanding. The number of shares has increased by 33.69% in one year.
| Shares Outstanding | 6.96M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 5.96% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 6.95M |
| Failed to Deliver (FTD) Shares | 1.99K |
| FTD / Avg. Volume | 4.48% |
Short Selling Information
The latest short interest is 65.73K, so 0.94% of the outstanding shares have been sold short.
| Short Interest | 65.73K |
| Short % of Shares Out | 0.94% |
| Short % of Float | 0.95% |
| Short Ratio (days to cover) | 0.92 |
Valuation Ratios
The PE ratio is -0.26 and the forward PE ratio is -0.05.
| PE Ratio | -0.26 |
| Forward PE | -0.05 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.77 |
| P/FCF Ratio | -0.31 |
| PEG Ratio | n/a |
Enterprise Valuation
Hepion Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.31, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.31 |
| Quick Ratio | 3.31 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.57 |
| Cash Flow / Debt | -352.75 |
| Interest Coverage | -5118.64 |
Financial Efficiency
Return on equity (ROE) is -6.72% and return on capital (ROIC) is -652.21%.
| Return on Equity (ROE) | -6.72% |
| Return on Assets (ROA) | -2.7% |
| Return on Capital (ROIC) | -652.21% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.22M |
| Employee Count | 22 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 409.02K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -85.18% in the last 52 weeks. The beta is 1.81, so Hepion Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.81 |
| 52-Week Price Change | -85.18% |
| 50-Day Moving Average | 0.65 |
| 200-Day Moving Average | 1.14 |
| Relative Strength Index (RSI) | 42.37 |
| Average Volume (20 Days) | 44.28K |
Income Statement
In the last 12 months, Hepion Pharmaceuticals had revenue of $0 and earned -$48.93M in profits. Earnings per share was $-12.32.
| Revenue | 0 |
| Gross Profit | -67.13K |
| Operating Income | -48.45M |
| Net Income | -48.93M |
| EBITDA | -49.26M |
| EBIT | - |
| Earnings Per Share (EPS) | -12.32 |
Balance Sheet
The company has $14.79M in cash and $209.02K in debt, giving a net cash position of $14.58M.
| Cash & Cash Equivalents | 14.79M |
| Total Debt | 209.02K |
| Net Cash | 14.58M |
| Retained Earnings | -224.63M |
| Total Assets | 3.72M |
| Working Capital | 814.33K |
Cash Flow
In the last 12 months, operating cash flow was -$40.89M and capital expenditures -$14.30K, giving a free cash flow of -$40.90M.
| Operating Cash Flow | -40.89M |
| Capital Expenditures | -14.30K |
| Free Cash Flow | -40.90M |
| FCF Per Share | -10.3 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
HEPA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2088.14% |
| FCF Yield | -996.15% |
Analyst Forecast
Currently there are no analyst rating for HEPA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 11, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | May 11, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -114.98 |
| Piotroski F-Score | 1 |